Advertisement

Topics

FDA Expands Approval of Ipsen’s Dysport for the Treatment of Lower Limb Spasticity in Adults

09:59 EDT 19 Jun 2017 | Speciality Pharma Journal

BASKING RIDGE, N.J.–(BUSINESS WIRE)–Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport®(abobotulinumtoxinA) for injection for the treatment of spasticity in adults, based on its supplemental Biologics License Application (sBLA) in lower limb spasticity. In …

Original Article: FDA Expands Approval of Ipsen’s Dysport for the Treatment of Lower Limb Spasticity in Adults

NEXT ARTICLE

More From BioPortfolio on "FDA Expands Approval of Ipsen’s Dysport for the Treatment of Lower Limb Spasticity in Adults"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...